# L-citrulline Injection in Patients Aged 6-21 Years Old with Sickle Cell Disease Presenting with Vaso-Occlusive Crisis (VOC)

> **NCT04852172** · PHASE1,PHASE2 · TERMINATED · sponsor: **Asklepion Pharmaceuticals, LLC** · enrollment: 30 (actual)

## Conditions studied

- Acute Vaso Occlusive Crisis (VOC)

## Interventions

- **DRUG:** L-citrulline
- **OTHER:** D5 1/2NS

## Key facts

- **NCT ID:** NCT04852172
- **Lead sponsor:** Asklepion Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-29
- **Primary completion:** 2024-02-29
- **Final completion:** 2024-02-29
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Impacted by viraemia resulting in higher than expected admissions
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04852172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04852172, "L-citrulline Injection in Patients Aged 6-21 Years Old with Sickle Cell Disease Presenting with Vaso-Occlusive Crisis (VOC)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04852172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*